Merck Expects 2024 Adjusted EPS Of $7.72-$7.77 Compared To Prior Guidance Of $$7.94-$8.04 And Consensus Of $7.74, Outlook Reflects a Net Negative Impact of $0.24/Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi Sankyo
Portfolio Pulse from Benzinga Newsdesk
Merck has revised its 2024 adjusted EPS guidance to $7.72-$7.77, down from the previous $7.94-$8.04, due to a $0.24/share negative impact from business transactions with Curon Biopharmaceutical and Daiichi Sankyo.
October 31, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck has lowered its 2024 adjusted EPS guidance due to a $0.24/share negative impact from business development transactions with Curon Biopharmaceutical and Daiichi Sankyo.
Merck's revised EPS guidance is lower than both its previous guidance and the consensus estimate, primarily due to the financial impact of its transactions with Curon Biopharmaceutical and Daiichi Sankyo. This is likely to negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100